Silvia Zamboni

Silvia Zamboni

Auto-generated profile, based on publicly available information

Silvia Zamboni


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PMPaola Margutti
Paola Margutti
ADAntonella D’ambrosio
Antonella D’ambrosio
SZSilvia Zamboni
Silvia Zamboni
The human microbiota is an intricate micro-ecosystem comprising a diverse range of dynamic microbial populations mainly consisting of bacteria, whose interactions with hosts strongly affect several physiological and pathological processes. The gut microbiota is being increasingly recognized as a critical player in maintaining homeostasis, contributing to the main functions of the intestine and distal organs such as the brain. However, gut dysbiosis, characterized by composition and function alterations of microbiota with intestinal barrier dysfunction has been linked to the development and progression of several pathologies, including intestinal inflammatory diseases, systemic autoimmune diseases, such as rheumatic arthritis, and neurodegenerative diseases, such as Alzheimer’s disease. Moreover, oral microbiota research has gained significant interest in recent years due to its potential impact on overall health. Emerging evidence on the role of microbiota–host interactions in health and disease has triggered a marked interest on the functional role of bacterial extracellular vesicles (BEVs) as mediators of inter-kingdom communication. Accumulating evidence reveals that BEVs mediate host interactions by transporting and delivering into host cells effector molecules that modulate host signaling pathways and cell processes, influencing health and disease. This review discusses the critical role of BEVs from the gut, lung, skin and oral cavity in the epithelium, immune system, and CNS interactions.

1 January 2007 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
MFMichela Flego
Michela Flego
AAAlessandro Ascione
Alessandro Ascione
SZSilvia Zamboni
Silvia Zamboni
MDMaria Luisa Dupuis
Maria Luisa Dupuis
VIValentina Imperiale
Valentina Imperiale
MCMaurizio Cianfriglia
Maurizio Cianfriglia
A hallmark of prion disease is the transformation of normal cellular prion protein (PrPc) into an infectious disease-associated isoform, (PrPsc). Anti-prion protein monoclonal antibodies are invaluable for structure-function studies of PrP molecules. Furthermore recent in vitro and in vivo studies indicate that anti-PrP monoclonal antibodies can prevent the incorporation of PrPc into propagating prions.

30 September 2009 in Antiviral Research
Verified
Journal Article
Closed access
AAAlessandro Ascione
Alessandro Ascione
BCBarbara Capecchi
Barbara Capecchi
LCLaura Campitelli
Laura Campitelli
VIValentina Imperiale
Valentina Imperiale
MFMichela Flego
Michela Flego
MCMaurizio Cianfriglia
Maurizio Cianfriglia

1 June 1992 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
SZSilvia Zamboni
Silvia Zamboni
AMAlessandra Mallano
Alessandra Mallano
MFMichela Flego
Michela Flego
AAAlessandro Ascione
Alessandro Ascione
MDMaria Luisa Dupuis
Maria Luisa Dupuis
MCMaurizio Cianfriglia
Maurizio Cianfriglia
We report the genetic construction and expression of a fusion protein between a single chain fragment variable (scFv) human antibody (E8) specific for CEA cell surface antigen and yeast cytosine deaminase (yCD). Sequences encoding for the scFvE8 human monoclonal antibody recognizing an epitope shared by CEACAM1, CEACAM3 and CEACAM5 isoforms were assembled with a monomer of yCD. The construct was placed under the transcriptional regulation of the lac promoter, and in frame with 6xHis tag for protein purification. After transformation and induction of E. coli, the protein was recovered from cell lysates and processed for purification. The scFvE8:yCD fusion protein possessed the binding specificity for melanoma (Mel P5) and colon carcinoma (LoVo) cell lines similar to its cognate human scFv antibody. The scFv8:yCD system showed the ability to render tumor cells susceptible to the far less toxic substrate 5-fluorocytosine (5-FC) by its enzymatic conversion into 5-fluorouracil (5-FU). In vitro pre-treatment of Mel P5 and LoVo cell lines with scFvE8:yCD followed by cell washing and incubation with 5-FC, resulted in significant cell killing supporting the utility of this fusion protein as an agent for tumor-selective prodrug activation. This study shows the feasibility of constructing fusion proteins in a prokaryotic cell based system consisting of a human scFv antibody and yCD to convert the antifungal agent 5-FC to 5-FU, one of the widely used anticancer agent.

10 September 2008 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
AMAlessandra Mallano
Alessandra Mallano
SZSilvia Zamboni
Silvia Zamboni
GCGiulia Carpinelli
Giulia Carpinelli
FSFilippo Santoro
Filippo Santoro
MFMichela Flego
Michela Flego
MCMaurizio Cianfriglia
Maurizio Cianfriglia
Background: The ability of cytosine deaminase (CD) to convert the antifungal agent 5-fluorocytosine (5-FC) into one of the most potent and largely used anticancer compound such as 5-fluorouracil (5-FU) raised considerable interest in this enzyme to model gene or antibody – directed enzyme-prodrug therapy (GDEPT/ADEPT) aiming to improve the therapeutic ratio (benefit versus toxic side-effects) of cancer chemotherapy. The selection and characterization of a human monoclonal antibody in single chain fragment (scFv) format represents a powerful reagent to allow in in vitro and in vivo detection of CD expression in GDEPT/ADEPT studies. Results: An enzymatic active recombinant CD from yeast (yCD) was expressed in E. coli system and used as antigen for biopanning approach of the large semi-synthetic ETH-2 antibody phage library. Several scFvs were isolated and specificity towards yCD was confirmed by Western blot and ELISA. Further, biochemical and functional investigations demonstrated that the binding of specific scFv with yCD did not interfere with the activity of the enzyme in converting 5-FC into 5-FU. Conclusion: The construction of libraries of recombinant antibody fragments that are displayed on the surface of filamentous phage, and the selection of phage antibodies against target antigens, have become an important biotechnological tool in generating new monoclonal antibodies for research and clinical applications. The scFvH5 generated by this method is the first human antibody which is able to detect yCD in routinary laboratory techniques without interfering with its enzymatic function.

9 September 2018
Verified
Book Chapter
Closed access
PDF file
MPMichela Pasello
Michela Pasello
AMAlessandra Mallano
Alessandra Mallano
MFMichela Flego
Michela Flego
SZSilvia Zamboni
Silvia Zamboni
AGAnna Maria Giudice
Anna Maria Giudice
Katia ScotlandiKatia Scotlandi
Katia Scotlandi